Discontinued — last reported Q3 '21
Financing
Stock Issuance Proceeds
Vertex Pharmaceuticals Stock Issuance Proceeds increased by 583.5% to $54.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 57.4%, from $34.30M to $54.00M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows an upward trend with a 5.8% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ3 2021
How to read this metric
Higher proceeds typically indicate increased employee participation in equity incentive plans, while lower proceeds may reflect reduced option exercise activity.
Detailed definition
Reflects the cash inflows received from the issuance of common stock, primarily driven by employee stock option exercise...
Peer comparison
Standard line item for companies with significant equity-based compensation programs for staff and management.
Metric ID:
cf_proceeds_from_stock_issuanceHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $37.94M | $13.80M | $34.71M | $33.70M | $64.40M | $36.60M | $51.60M | $14.20M | $58.60M | $15.40M | $46.40M | $16.90M | $55.00M | $8.40M | $34.30M | $16.70M | $49.10M | $7.90M | $54.00M |
| QoQ Change | — | -63.6% | +151.6% | -2.9% | +91.1% | -43.2% | +41.0% | -72.5% | +312.7% | -73.7% | +201.3% | -63.6% | +225.4% | -84.7% | +308.3% | -51.3% | +194.0% | -83.9% | +583.5% |
| YoY Change | — | — | — | — | +69.8% | +165.3% | +48.7% | -57.9% | -9.0% | -57.9% | -10.1% | +19.0% | -6.1% | -45.5% | -26.1% | -1.2% | -10.7% | -6.0% | +57.4% |
Range$7.90M – $64.40M
CAGR+8.2%
Avg YoY Growth+8.7%
Median YoY Growth-6.1%
Stock Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's stock issuance proceeds?
- Vertex Pharmaceuticals (VRTX) reported stock issuance proceeds of $54.00M in Q4 2025.
- How has Vertex Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Vertex Pharmaceuticals's stock issuance proceeds increased by 57.4% year-over-year, from $34.30M to $54.00M.
- What is the long-term trend for Vertex Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's stock issuance proceeds has grown at a 5.8% compound annual growth rate (CAGR), from $102.00M to $127.70M.
- What does stock issuance proceeds mean?
- Cash received from the sale of company stock to employees or investors.